Data / Drug companies / Caplin Steriles Limited
Caplin Steriles Limited: 88 products in the FDA NDC directory, labeler code 65145
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Caplin Steriles Limited (labeler code 65145) lists 88 products in the FDA National Drug Code Directory, covering 41 finished drugs by generic name. By type: 88 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 17, 2026.
The request: Watch Caplin Steriles Limited (FDA labeler code 65145): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 65145
- Products in commercial distribution
- 88
- Packages
- 91
- Finished drugs by generic name
- 41
- Prescription products
- 88
- Over the counter products
- 0
- Flagged as original packager
- 85 of 85 products that carry the flag
- Started marketing in the last 12 months
- 27
- Earliest marketing start
- April 30, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 88 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 88 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 32 | 36.4% |
| Injection, solution | 32 | 36.4% |
| Solution/ drops | 10 | 11.4% |
| Solution | 7 | 8% |
| Injection, solution, concentrate | 3 | 3.4% |
| Injection, suspension | 2 | 2.3% |
| Emulsion | 1 | 1.1% |
| Injection, emulsion | 1 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Potassium phosphates | 65145-196 | Injection, solution, concentrate | Generic drugs (ANDA) | September 17, 2026 |
| Potassium phosphates | 65145-195 | Injection, solution, concentrate | Generic drugs (ANDA) | September 17, 2026 |
| Potassium phosphates | 65145-194 | Injection, solution, concentrate | Generic drugs (ANDA) | September 17, 2026 |
| Nicardipine Hydrochloride | 65145-198 | Injection | Generic drugs (ANDA) | June 25, 2026 |
| Nicardipine Hydrochloride | 65145-197 | Injection | Generic drugs (ANDA) | June 25, 2026 |
| Milrinone Lactate in 5% Dextrose | 65145-177 | Injection, solution | Generic drugs (ANDA) | June 25, 2026 |
| Milrinone Lactate in 5% Dextrose | 65145-176 | Injection, solution | Generic drugs (ANDA) | June 25, 2026 |
| Foscarnet Sodium | 65145-191 | Injection, solution | Generic drugs (ANDA) | May 20, 2026 |
| Calcium Gluconate | 65145-172 | Injection, solution | Generic drugs (ANDA) | May 13, 2026 |
| Calcium Gluconate | 65145-171 | Injection, solution | Generic drugs (ANDA) | May 13, 2026 |
| Calcium Gluconate | 65145-170 | Injection, solution | Generic drugs (ANDA) | May 13, 2026 |
| Phenylephrine hydrochloride | 65145-117 | Injection | Generic drugs (ANDA) | April 28, 2026 |
| Phenylephrine hydrochloride | 65145-116 | Injection | Generic drugs (ANDA) | April 28, 2026 |
| Phenylephrine hydrochloride | 65145-115 | Injection | Generic drugs (ANDA) | April 28, 2026 |
| Argatroban | 65145-126 | Injection | Generic drugs (ANDA) | April 17, 2026 |
| Prochlorperazine Edisylate | 65145-119 | Injection | Generic drugs (ANDA) | April 8, 2026 |
| Desmopressin Acetate | 65145-184 | Injection, solution | Generic drugs (ANDA) | March 16, 2026 |
| Desmopressin Acetate | 65145-183 | Injection, solution | Generic drugs (ANDA) | March 16, 2026 |
| Sodium phosphates | 65145-202 | Injection, solution | Generic drugs (ANDA) | March 10, 2026 |
| Sodium phosphates | 65145-201 | Injection, solution | Generic drugs (ANDA) | March 10, 2026 |
| Sodium phosphates | 65145-200 | Injection, solution | Generic drugs (ANDA) | March 10, 2026 |
| Methylprednisolone Acetate | 65145-193 | Injection, suspension | Generic drugs (ANDA) | February 6, 2026 |
| Methylprednisolone Acetate | 65145-192 | Injection, suspension | Generic drugs (ANDA) | February 6, 2026 |
| Etomidate | 65145-128 | Injection, solution | Generic drugs (ANDA) | February 5, 2026 |
| Etomidate | 65145-127 | Injection, solution | Generic drugs (ANDA) | February 5, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.